Literature DB >> 19968650

Association of childhood perennial allergic rhinitis with subclinical airflow limitation.

G Ciprandi1, M Capasso.   

Abstract

BACKGROUND: Allergic rhinitis (AR) is a relevant risk factor for the onset of asthma, and a close association exists between the nose and the bronchi. Recently, it has been evidenced that the duration of AR and mite allergy represent high risks for spirometric impairment in allergic adults. AIM: To evaluate a group of AR children, without bronchial symptoms, to investigate spirometric impairments.
METHODS: Two hundred children with moderate-severe AR were consecutively evaluated. Clinical examination, skin prick test, and spirometry were performed in all children.
RESULTS: Thirty-one percent of the children had forced expiratory flow at 25% and 75% of the pulmonary volume (FEF25-75%)<80% of the predicted values and 11% had both forced expiratory volume in 1 s and FEF25-75%<80% of the predicted values. Rhinitis duration and sensitization to house dust mites were significantly associated with impaired values of these spirometric parameters.
CONCLUSION: This study highlights the close link between the upper and the lower airways and the role of some risk factors, such as long duration and mite sensitization, as early prognostic markers of bronchial involvement in children with AR and perceiving nasal symptoms alone.

Entities:  

Mesh:

Year:  2009        PMID: 19968650     DOI: 10.1111/j.1365-2222.2009.03399.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  2 in total

1.  Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria.

Authors:  Erminia Ridolo; Cristoforo Incorvaia; Giorgio Ciprandi
Journal:  Acta Biomed       Date:  2021-05-12

2.  Inflammation Markers and FEF25-75: A Relevant Link in Children With Asthma.

Authors:  Maria Angela Tosca; Michela Silvestri; Nicoletta Solari; Giovanni Arturo Rossi; Giorgio Ciprandi
Journal:  Allergy Asthma Immunol Res       Date:  2015-10-07       Impact factor: 5.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.